Pyraloxime chloride veterinary-grade API (PAM-Cl; 2-[(hydroxyimino)methyl]-1-methylpyridinium chloride) is handled as a narrow therapeutic index oxime rather than a feed-grade salt. The formulation routes below are limited to dosage forms that preserve the quaternary ammonium active site against alkaline hydrolysis and oxygen-mediated chromophore degradation. In commercial batch records, PAM-Cl is classified as a low-volume, high-potency active pharmaceutical ingredient; this restricts the choice of excipients, metal wetted surfaces, and in-process pH bounds. The application set is limited to species and dosage forms supported by emergency-use veterinary protocols: aqueous injectables, oral solids, water-soluble powders, granules, feed premixes, and extemporaneously compounded solutions.

Preparation of a sterile aqueous PAM-Cl injection at 50 mg/mL labeled potency sets the active addition ratio at 5.0% w/v after correction for API water content. The batch vessel is a jacketed 316L stainless-steel tank with bottom-entry homogenizer; it is nitrogen-purged to a dissolved oxygen endpoint below 0.2 mg/L before API addition because the quaternary oxime chromophore is oxygen-sensitive in solution. The pH is adjusted to 3.5–4.5 with dilute hydrochloric acid and continuously logged by an inline pH meter calibrated at 20 ± 2 °C. Compendial release for the injection is based on 21 CFR 211.167 sterility, USP <1> injectable product requirements, USP <788> particulate matter, and VICH GL18(R2) related-impurity limits; EU-bound batches add Ph. Eur. 5.1.1 and Ph. Eur. 2.2.3. The downstream sterile-filtration step uses a 0.45 μm prefilter followed by a 0.22 μm polyvinylidene fluoride membrane; the filtered solution is filled into Type I glass vials under nitrogen and closed with fluoropolymer-coated chlorobutyl stoppers. Terminal dosage forms are 10 mL and 20 mL single-dose vials for intravenous or intramuscular administration. The observed batch failure mode on production lines that reuse the same homogenizer for alkaline sodium bicarbonate injections is pH drift above 4.5 after cleaning; clean-in-place validation with pH and conductivity recovery standards prevents this.

Why Do Prefilled Syringe Elastomers Drive a Narrower pH Window Than Glass Vial Filling?

Prefilled syringe assembly introduces three additional variables not present in vial filling: elastomer extractables, plunger friction, and residual oxygen through the barrel wall. In equine and working-dog field antidote kits, the PAM-Cl solution is either filled at 50 mg/mL or diluted to 20 mg/mL with 0.9% sodium chloride to reduce intramuscular injection pain and syringe-plunger back pressure. The active addition ratio at the point of fill is therefore 5.0% w/v for the undiluted configuration and 2.0% w/v for the diluted configuration. Compliance for this step is governed by EU GMP Annex 1 for sterile manufacturing where the product is placed on the market, and by USP <797> for compounded sterile preparations in hospital or field-infirmary settings. Production equipment includes a closed-system transfer device inside an ISO 14644-1 Class 5 clean air workstation, steam-sterilized silicone tubing, and light-protected polyethylene overwrap; terminal product types are 5 mL and 10 mL Luer-lock syringes. The dominant failure signature in this format is acid pH drift caused by elastomeric stoppers; a validated stopper wash and vacuum-dry cycle of 4 h at 40 °C reduces extractable fatty acids. The syringes are stored at 2–8 °C because room-temperature storage shortens the period in which pH remains above 3.0.

When PAM-Cl is dry-blended for nonsterile oral solids in companion-animal emergency kits, the key process risk is not blend segregation but moisture uptake by the quaternary ammonium oxime. A representative 100 mg tablet core is based on a 250 mg total core weight with 40.0% PAM-Cl, 46.0% lactose monohydrate, 10.0% microcrystalline cellulose, 3.0% crospovidone, and 1.0% magnesium stearate; the active addition ratio is therefore 40.0% w/w. Capsulation at 150 mg strength uses the same interior fill with hard gelatin capsules to avoid direct compression of high-dose cores. Compliance is established under 21 CFR 211.110 in-process blend uniformity, USP <795> for compounded nonsterile preparations, and VICH GL1 analytical procedure validation. The production line uses dry granulation by slugging rather than wet granulation to avoid hydrolysis; the granulate is milled through a 1.0 mm aperture screen and compressed on a rotary tablet press with 8 kN precompression and 15 kN main compression force. Terminal dosage forms are 50 mg and 100 mg tablets and 150 mg hard gelatin capsules for oral adjunctive therapy. Because quaternary ammonium oximes have low lipid permeability, oral absorption in dogs and cats is slower than intramuscular administration; the dosage form is used only when veterinary prescribing determines that gastrointestinal transit and severity allow adjunctive administration. Open blending areas above 60% relative humidity and alkaline lubricants such as magnesium trisilicate are excluded.

Water-Soluble Powder Formulation Binds Dissolution Rate to Bicarbonate Alkalinity

Water-soluble powder formulation binds the reconstituted solution pH to the acid buffer rather than relying on the end user’s water quality. In flock or kennel emergency water medication, the PAM-Cl powder is prepared at 10.0% w/w active content with 85.0% mannitol as a non-reducing crystalline carrier and 5.0% citric acid as the acidifying buffer; this gives a fixed stock batch addition ratio of 100 mg/g. The final drinking solution is dose-driven: a prescribed dose of 10 mg/kg in a species with 100 mL/kg/day water intake gives 100 mg/L PAM-Cl. Compliance for a manufactured powder is evaluated under VICH GL18(R2) related-impurity limits, Ph. Eur. 5.1.4 microbiological quality of non-sterile products, and 21 CFR 211.165 finished-product release; where no regional marketing authorization exists, compounding follows USP <795>. The downstream process uses a high-shear mixer at 1,200 rpm for 8 min, followed by fluid-bed drying at 35 °C if granulation is needed, and low-humidity filling into foil sachets at 25% RH. Terminal product types are 5 g, 50 g, and 250 g foil sachets or HDPE jars. Published data for PAM-Cl water-soluble powders in bicarbonate-rich hard water are limited; the production limit is therefore set conservatively: raw water should be pre-acidified to pH 5.5 or lower before reconstitution, and stock solutions are held at 2–8 °C for no more than 24 h.

Granule and Premix Dilution Ratios in Non-Food Species Emergency Feed Medication

Granule and premix formats are restricted to non-food species facilities, zoological collections, and emergency feed medication in livestock under documented exclusion from slaughter. The active premix is prepared at 5.0% w/w PAM-Cl on a citric acid-coated sodium chloride carrier, and the premix is diluted 1:100 with non-alkaline feed meal to a final feed inclusion of 500 mg/kg. Compliance for the premix manufacturing step follows 21 CFR 225 current good manufacturing practice for medicated feeds and VICH GL11(R) residue methodology where a withdrawal period must be justified; finished feed-release sampling follows VICH GL1 and 21 CFR 211.110 uniformity principles. Production uses a ribbon mixer with a 15 kg minimum working capacity, a 10 mm aperture screen mill, and geometric dilution of the API before the final blend at 25 rpm for 15 min; moisture after blending must remain below 5.0%. Terminal product types are 1 kg and 5 kg HDPE drums and 20 kg paper sacks with inner polyethylene liners. The main incompatibility is with calcium- and magnesium-mineral premixes that raise the feed pH; PAM-Cl premix lines must also be segregated from alkaline veterinary feed ingredients and dried fully after cleaning because moisture above 60% RH accelerates hydrolysis.

For veterinary hospital compounding, a PAM-Cl solution is prepared from bulk API by dissolving 1 g into 20 mL of sterile 0.9% sodium chloride or deionized water to reach 50 mg/mL, equivalent to an addition ratio of 5.0% w/v. The solution is prepared in a USP <797>-compliant ISO Class 5 laminar-airflow workstation or compounding aseptic isolator; batch release testing follows 21 CFR 211.165 potency and USP <85> bacterial endotoxins where parenteral use is intended. The production step uses a closed-system transfer device, a 0.22 μm membrane filter for sterilization, and amber 10 mL vials or patient-specific syringes as terminal product types. Compounded aqueous PAM-Cl is stored at 2–8 °C and protected from light; unprotected holding at 25 °C is limited to 4 h because of pH-dependent degradation. Bulk API storage requires double polyethylene bags inside sealed aluminum cans with desiccant at ≤25 °C; open containers exposed to ambient moisture above 60% RH must be quarantined for assay because the quaternary ammonium oxime is hygroscopic.